Galaxy Biomedical Investment Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 1,105.975 million compared to CNY 781.439 million a year ago. Operating income was CNY 155.737 million compared to operating loss of CNY 1,137.166 million a year ago. Net income was CNY 58.309 million compared to net loss of CNY 1,366.532 million a year ago. Basic earnings per share from continuing operations was CNY 0.053 compared to basic loss per share from continuing operations of CNY 1.2424 a year ago.